Editorial: Autoimmune complications of modern cancer therapies

Front Immunol. 2024 Jan 5:14:1357825. doi: 10.3389/fimmu.2023.1357825. eCollection 2023.

Nora Möhn^{1

2}, Mirjam Renovanz^{3

4}, David Hagin⁵, Thomas Skripuletz^{1

2}

¹ Department of Neurology, Hannover Medical School, Hannover, Germany.
² Immune Cooperative Oncology Group, Comprehensive Cancer Center Hannover (ICOG-CCCH), Hannover, Germany.
³ Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tuebingen, Hertie Institute for Clinical Brain Research, Tuebingen, Germany.
⁴ Department of Neurosurgery, University Hospital Tuebingen, Tuebingen, Germany.
⁵ Department of Immunology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

No abstract available

Keywords: JAK1 and JAK2 inhibitors; biomarkers; immune checkpoint inhibitor (ICI); immunotherapy; irAE.

Publication types

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.